Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China:Correlation Between Recurrence and Drug ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2018-2021

ABSTRACT

This prospective observational study is going to figure out the safety and efficacy of denosumab as an post-operative strategy.All the patients enrolled will take denosumab according to the protocols.We focus on the recurrence rate after the drug withdrawl and possibility of malignant transformation. Detailed Description This prospective observational study is going to figure out the safety and efficacy of denosumab as an post-operative strategy. This study only included patients who meet all the following criteria: (1) With treatment-naïve sacral giant-cell tumor (GCT) firstly treated in our center (for referral patients, only those with definite diagnosis were included); (2) Being diagnosed with classic giant-cell tumor of bone (GCTB) by puncture pathology prior to treatment (for referral patients, definite diagnosis shall be made by the Pathology Department in our center through pathology consultation on tissue sections); (3) previously denosumab-naïve. Data collection:The following data of patients included in this study were collected: (1) basic information: age, gender; (2) pathological data: puncture pathological diagnosis, and postoperative pathological findings; (3) the imaging findings (including X-ray, CT, Magnetic resonance(MR), Positron Emission Tomography-Computed Tomography(PET-CT)) and functional assessment of patients in the neoadjuvant denosumab group before and after the use of denosumab; (4) intraoperative blood loss, and duration of operation; (5) imaging findings in postoperative follow-up re-examination and outcome. functional assessment: For sacral giant cell tumor:The Motor Urination defecation(MUD) scoring system published on Spine by our center in 2016 , which include three domains (motor function and sensation of lower limbs [M], urination and uriesthesia [U], and Defecation and rectal sensation [D]) with three items in each domain (each item can be scored by 0, 1, 2 or 3, and the maximum score is 27), was applied in the functional assessment of sacral nerves. For GCT occurs in Limbs ,we use Musculoskeletal Tumor Society (MSTS) 93 to record the function. All the patients enrolled will take denosumab according to the protocols:denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle,them take it monthly till 1 year after the surgery.We focus on the recurrence rate after the drug withdrawl and possibility of malignant transformation. More... »

URL

https://clinicaltrials.gov/show/NCT03358212

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This prospective observational study is going to figure out the safety and efficacy of denosumab as an post-operative strategy.All the patients enrolled will take denosumab according to the protocols.We focus on the recurrence rate after the drug withdrawl and possibility of malignant transformation.\n\nDetailed Description\nThis prospective observational study is going to figure out the safety and efficacy of denosumab as an post-operative strategy. This study only included patients who meet all the following criteria: (1) With treatment-na\u00efve sacral giant-cell tumor (GCT) firstly treated in our center (for referral patients, only those with definite diagnosis were included); (2) Being diagnosed with classic giant-cell tumor of bone (GCTB) by puncture pathology prior to treatment (for referral patients, definite diagnosis shall be made by the Pathology Department in our center through pathology consultation on tissue sections); (3) previously denosumab-na\u00efve. Data collection:The following data of patients included in this study were collected: (1) basic information: age, gender; (2) pathological data: puncture pathological diagnosis, and postoperative pathological findings; (3) the imaging findings (including X-ray, CT, Magnetic resonance(MR), Positron Emission Tomography-Computed Tomography(PET-CT)) and functional assessment of patients in the neoadjuvant denosumab group before and after the use of denosumab; (4) intraoperative blood loss, and duration of operation; (5) imaging findings in postoperative follow-up re-examination and outcome. functional assessment: For sacral giant cell tumor:The Motor Urination defecation(MUD) scoring system published on Spine by our center in 2016 , which include three domains (motor function and sensation of lower limbs [M], urination and uriesthesia [U], and Defecation and rectal sensation [D]) with three items in each domain (each item can be scored by 0, 1, 2 or 3, and the maximum score is 27), was applied in the functional assessment of sacral nerves. For GCT occurs in Limbs ,we use Musculoskeletal Tumor Society (MSTS) 93 to record the function. All the patients enrolled will take denosumab according to the protocols:denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle,them take it monthly till 1 year after the surgery.We focus on the recurrence rate after the drug withdrawl and possibility of malignant transformation.", 
    "endDate": "2021-06-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03358212", 
    "keywords": [
      "safety", 
      "efficacy", 
      "denosumab", 
      "Giant Cell", 
      "IN", 
      "Recurrence", 
      "prospective observational study", 
      "patient", 
      "protocol", 
      "recurrence rate", 
      "drug", 
      "possibility", 
      "malignant transformation", 
      "criterion", 
      "definite diagnosis", 
      "pathology", 
      "Pathology Department", 
      "tissue section", 
      "Data Collection", 
      "basic information", 
      "age", 
      "Gender Identity", 
      "pathological diagnosis", 
      "pathological finding", 
      "imaging finding", 
      "x-ray", 
      "CT", 
      "Magnetic Resonance Spectroscopy", 
      "positron emission", 
      "computed tomography", 
      "PET-CT", 
      "functional assessment", 
      "neoadjuvant", 
      "blood loss", 
      "duration", 
      "operation", 
      "re-examination", 
      "defecation", 
      "scoring system", 
      "spine", 
      "domain", 
      "motor function", 
      "sensation", 
      "low limb", 
      "Urination", 
      "maximum", 
      "nerve", 
      "Extremity", 
      "society", 
      "subcutaneous injection", 
      "loading dose", 
      "first cycle", 
      "General Surgery"
    ], 
    "name": "Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China\uff1aCorrelation Between Recurrence and Drug Withdrawl", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03358212"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00026.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.411634.5", 
        "type": "Organization"
      }
    ], 
    "startDate": "2018-03-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1093/annonc/mdv307", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004972771"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-0578", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007580803"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-015-4634-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026452907", 
          "https://doi.org/10.1245/s10434-015-4634-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/pas.0000000000000506", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029792126"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70277-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038842118"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2106/jbjs.m.01332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068903672"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03358212"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03358212'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03358212'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03358212'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03358212'


 

This table displays all metadata directly associated to this object as RDF triples.

91 TRIPLES      16 PREDICATES      74 URIs      62 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03358212 schema:about anzsrc-for:3053
2 schema:description This prospective observational study is going to figure out the safety and efficacy of denosumab as an post-operative strategy.All the patients enrolled will take denosumab according to the protocols.We focus on the recurrence rate after the drug withdrawl and possibility of malignant transformation. Detailed Description This prospective observational study is going to figure out the safety and efficacy of denosumab as an post-operative strategy. This study only included patients who meet all the following criteria: (1) With treatment-naïve sacral giant-cell tumor (GCT) firstly treated in our center (for referral patients, only those with definite diagnosis were included); (2) Being diagnosed with classic giant-cell tumor of bone (GCTB) by puncture pathology prior to treatment (for referral patients, definite diagnosis shall be made by the Pathology Department in our center through pathology consultation on tissue sections); (3) previously denosumab-naïve. Data collection:The following data of patients included in this study were collected: (1) basic information: age, gender; (2) pathological data: puncture pathological diagnosis, and postoperative pathological findings; (3) the imaging findings (including X-ray, CT, Magnetic resonance(MR), Positron Emission Tomography-Computed Tomography(PET-CT)) and functional assessment of patients in the neoadjuvant denosumab group before and after the use of denosumab; (4) intraoperative blood loss, and duration of operation; (5) imaging findings in postoperative follow-up re-examination and outcome. functional assessment: For sacral giant cell tumor:The Motor Urination defecation(MUD) scoring system published on Spine by our center in 2016 , which include three domains (motor function and sensation of lower limbs [M], urination and uriesthesia [U], and Defecation and rectal sensation [D]) with three items in each domain (each item can be scored by 0, 1, 2 or 3, and the maximum score is 27), was applied in the functional assessment of sacral nerves. For GCT occurs in Limbs ,we use Musculoskeletal Tumor Society (MSTS) 93 to record the function. All the patients enrolled will take denosumab according to the protocols:denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle,them take it monthly till 1 year after the surgery.We focus on the recurrence rate after the drug withdrawl and possibility of malignant transformation.
3 schema:endDate 2021-06-01T00:00:00Z
4 schema:keywords CT
5 Data Collection
6 Extremity
7 Gender Identity
8 General Surgery
9 Giant Cell
10 IN
11 Magnetic Resonance Spectroscopy
12 PET-CT
13 Pathology Department
14 Recurrence
15 Urination
16 age
17 basic information
18 blood loss
19 computed tomography
20 criterion
21 defecation
22 definite diagnosis
23 denosumab
24 domain
25 drug
26 duration
27 efficacy
28 first cycle
29 functional assessment
30 imaging finding
31 loading dose
32 low limb
33 malignant transformation
34 maximum
35 motor function
36 neoadjuvant
37 nerve
38 operation
39 pathological diagnosis
40 pathological finding
41 pathology
42 patient
43 positron emission
44 possibility
45 prospective observational study
46 protocol
47 re-examination
48 recurrence rate
49 safety
50 scoring system
51 sensation
52 society
53 spine
54 subcutaneous injection
55 tissue section
56 x-ray
57 schema:name Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China:Correlation Between Recurrence and Drug Withdrawl
58 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03358212
59 schema:sdDatePublished 2019-03-07T15:27
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher N09c465cae77d400cb1a583f12017d6f7
62 schema:sponsor https://www.grid.ac/institutes/grid.411634.5
63 schema:startDate 2018-03-01T00:00:00Z
64 schema:subjectOf sg:pub.10.1245/s10434-015-4634-9
65 https://doi.org/10.1016/s1470-2045(13)70277-8
66 https://doi.org/10.1093/annonc/mdv307
67 https://doi.org/10.1097/pas.0000000000000506
68 https://doi.org/10.1158/1078-0432.ccr-12-0578
69 https://doi.org/10.2106/jbjs.m.01332
70 schema:url https://clinicaltrials.gov/show/NCT03358212
71 sgo:license sg:explorer/license/
72 sgo:sdDataset clinical_trials
73 rdf:type schema:MedicalStudy
74 N09c465cae77d400cb1a583f12017d6f7 schema:name Springer Nature - SN SciGraph project
75 rdf:type schema:Organization
76 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
77 rdf:type schema:DefinedTerm
78 sg:pub.10.1245/s10434-015-4634-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026452907
79 https://doi.org/10.1245/s10434-015-4634-9
80 rdf:type schema:CreativeWork
81 https://doi.org/10.1016/s1470-2045(13)70277-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038842118
82 rdf:type schema:CreativeWork
83 https://doi.org/10.1093/annonc/mdv307 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004972771
84 rdf:type schema:CreativeWork
85 https://doi.org/10.1097/pas.0000000000000506 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029792126
86 rdf:type schema:CreativeWork
87 https://doi.org/10.1158/1078-0432.ccr-12-0578 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007580803
88 rdf:type schema:CreativeWork
89 https://doi.org/10.2106/jbjs.m.01332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068903672
90 rdf:type schema:CreativeWork
91 https://www.grid.ac/institutes/grid.411634.5 schema:Organization
 




Preview window. Press ESC to close (or click here)


...